SCHEMBL4511525

SCHEMBL4511525

CC(=O)Nc1nc(C)c(-c2csc(Nc3cccc(Cl)c3)n2)s1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 8/20 0.80
KMT2A Q03164 8/20 0.80
MAPT P10636 6/20 0.80
ALDH1A1 P00352 4/20 0.79
CYP1A2 P05177 3/20 0.79
CYP2C19 P33261 3/20 0.79
KDM4E B2RXH2 3/20 0.79
SMN1; SMN2 Q16637 2/20 0.79
CYP3A4 P08684 2/20 0.79
CYP2D6 P10635 2/20 0.79
CYP2C9 P11712 2/20 0.79
HPGD P15428 1/20 0.79
PIK3CG P48736 4/20 0.76
MITF O75030 1/20 0.76
RAB9A P51151 1/20 0.76
POLB P06746 2/20 0.72
LMNA P02545 2/20 0.72
MCL1 Q07820 1/20 0.72
NPSR1 Q6W5P4 2/20 0.67
USP2 O75604 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4518472 0.88 MEN1 (0.78) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL4510185 0.88 MEN1 (0.98) MEN1KMT2AMAPTALDH1A1CYP1A2
SCHEMBL4514872 0.87 MEN1 (0.85) MEN1KMT2AMAPTALDH1A1CYP1A2
SCHEMBL4524238 0.87 MEN1 (0.84) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL4531290 0.87 PIK3CG (1.00) MEN1KMT2AMAPTALDH1A1CYP1A2
SCHEMBL4532774 0.87 MEN1 (0.85) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL4531920 0.86 PIK3CG (0.79) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL4519779 0.86 MEN1 (0.79) MEN1KMT2AMAPTALDH1A1KDM4E
SCHEMBL4512539 0.86 MEN1 (0.83) MEN1KMT2AMAPTALDH1A1CYP1A2
SCHEMBL4534326 0.86 MEN1 (0.83) MEN1KMT2AMAPTALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802861-B2 Thiazole derivatives and use thereof MERCK SERONO SA (CH) 2014-08-12 US claimed
US-20090029998-A1 Thiazole Derivatives and Use Thereof APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2009-01-29 US claimed
EP-1709019-B1 THIAZOLE DERIVATIVES AND USE THEREOF APPLIED RESEARCH SYSTEMS (AN) 2007-08-08 EP claimed
US-9150561-B2 Thiazole derivatives and use thereof MERCK SERONO S.A. (CH) 2015-10-06 US disclosed
US-20140228365-A1 THIAZOLE DERIVATIVES AND USE THEREOF MERCK SERONO S.A. (CH) 2014-08-14 US disclosed
US-20140228365-A1 THIAZOLE DERIVATIVES AND USE THEREOF MERCK SERONO S.A. (CH) 2014-08-14 US disclosed
US-8802861-B2 Thiazole derivatives and use thereof MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-8802861-B2 Thiazole derivatives and use thereof MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-8802861-B2 Thiazole derivatives and use thereof MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-20090029998-A1 Thiazole Derivatives and Use Thereof APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2009-01-29 US disclosed
US-20090029998-A1 Thiazole Derivatives and Use Thereof APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2009-01-29 US disclosed
US-20090029998-A1 Thiazole Derivatives and Use Thereof APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140228365-A1 THIAZOLE DERIVATIVES AND USE THEREOF PF4, TEC, PDGFRB MEN1 1164/4885KMT2A 4760/4885MAPT 4151/4885
US-20090029998-A1 Thiazole Derivatives and Use Thereof PDGFRB, PDGFRA, TEC MEN1 1761/4885KMT2A 4737/4885MAPT 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.